Oncolytics Biotech Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as Chief Business Officer. Mr. Aromando most recently served as...